Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (512)	6/12/1998 11:33:00 PM
From: Mr. Forthright	Respond to of 5402

My problem is not necessarely with the product but mainly with the hype.

To: chirodoc who wrote (512)	6/13/1998 12:06:00 AM
From: drdan	Read Replies (2) \| Respond to of 5402

I'm back. Thought I might take a moment to sum up the key points from this extract- 1)the pfc product is compatible with mammalian red cells 2) the pfc compound with additional fluid to make up for any blood volume loss got oxygen to tissues as well as a person's own red cells 3) the issue of increased heart rate and cardiac output May or may not be of significance in humans with normal cardiac function. While this info is from a very small cohort of dogs, I feel that this is promising info. This is not a shlock product, regardless of what anyone says...